Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen. (11th February 2014)

• Record Type: Journal Article
• Authors: van Veen, J. J.; Maclean, R. M.; Hampton, K. K.; Hamer, A.; Makris, M.
• Is Part Of: Haemophilia. Volume 20:Number 4(2014:Jul.)
• Page Start: 587
• Page End: 592
• Publication Date: 2014-02-11
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12365
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae12365-abs-0001"> <title>Summary</title> <p>Major surgery in persons with haemophilia A and inhibitors is increasingly being performed. Both recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC) are used to cover surgery but it remains unclear what the optimal dosing schedules are. We describe the use of a hybrid regimen in four inhibitor patients undergoing eight major surgical procedures using rFVIIa in the initial 2–6 postoperative days followed by FEIBA^® for the remaining period. All patients were also treated with tranexamic acid while receiving rFVIIa. We performed six major orthopaedic procedures, one emergency orchidectomy and one open appendectomy. The dosing schedules were at the higher end of those described in the literature but within the recommendations of the summary of product characteristics. Despite this, we encountered non‐surgical bleeding in four of eight episodes. Three of these occurred in one individual suggesting a patient factor. The overall outcome was good for all episodes. The hybrid regimen combines flexibility of dose and dosing frequency of rFVIIa in the immediate postoperative setting with the advantage of a reduced dosing frequency with FEIBA^® in the subsequent days. This study also emphasizes that surgical procedures in this patient group remain a challenge.</p> </abstract>